Journal of Yeungnam Medical Science

Review article

Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology: In Cheol Yoon, Jong Ryeol Eun; Yeungnam Univ J Med. 2019;36(2):67-77. Published online April 11, 2019; DOI: https://doi.org/10.12701/yujm.2019.00171

9,365 View
200 Download
5 Crossref

The paradigm of chronic liver diseases has been shifting. Although hepatitis B and C viral infections are still the main causes of liver cirrhosis and hepatocellular carcinoma (HCC), the introduction of effective antiviral drugs may control or cure them in the near future. In contrast, the burden of nonalcoholic fatty liver disease (NAFLD) has been increasing for decades, and 25 to 30% of the general population in Korea is estimated to have NAFLD. Over 10% of NAFLD patients may have nonalcoholic steatohepatitis (NASH), a severe form of NAFLD. NASH can progress to cirrhosis and HCC. NASH is currently the second leading cause to be placed on the liver transplantation list in the United States. NAFLD is associated with obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome. The pathophysiology is complex and associated with lipotoxicity, inflammatory cytokines, apoptosis, and insulin resistance. The only proven effective treatment is weight reduction by diet and exercise. However, this may not be effective for advanced fibrosis or cirrhosis. Therefore, effective drugs are urgently needed for treating these conditions. Unfortunately, no drugs have been approved for the treatment of NASH. Many pharmaceutical companies are trying to develop new drugs for the treatment of NASH. Some of them are in phase 2 or 3 clinical trials. Here, pharmacologic therapies in clinical trials, as well as the basic principles of drug therapy, will be reviewed, focusing on pathophysiology.

Citations

Citations to this article as recorded by

Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
Tharani Senavirathna, Armaghan Shafaei, Ricky Lareu, Lois Balmer
Antioxidants.2024; 13(4): 485. CrossRef
Effect of Lactobacillus rhamnosus hsryfm 1301 Fermented Milk on Lipid Metabolism Disorders in High-Fat-Diet Rats
Hengxian Qu, Lina Zong, Jian Sang, Yunchao Wa, Dawei Chen, Yujun Huang, Xia Chen, Ruixia Gu
Nutrients.2022; 14(22): 4850. CrossRef
Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease
Yuanqiang Ma, Gyurim Lee, Su-Young Heo, Yoon-Seok Roh
Antioxidants.2021; 11(1): 91. CrossRef
Elevated 1-h post-load plasma glucose levels in normal glucose tolerance children with obesity is associated with early carotid atherosclerosis
Suna Kılınç, Tuna Demirbaş, Enver Atay, Ömer Ceran, Zeynep Atay
Obesity Research & Clinical Practice.2020; 14(2): 136. CrossRef
Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
L. Kořínková, V. Pražienková, L. Černá, A. Karnošová, B. Železná, J. Kuneš, Lenka Maletínská
Frontiers in Endocrinology.2020;[Epub] CrossRef

Original Article

High levels of carcinoembryonic antigen and smoking might be markers of colorectal adenoma in Korean males aged 40-49 years.: In Cheol Yoon, Jeong Hyeon Cho, Heejin Choi, Young Hoon Choi, Kyu Min Lim, Sung Hwa Choi, Jae Ho Han, Hyeon Ju Jeong, Hong Sub Lee; Yeungnam Univ J Med. 2016;33(1):13-20. Published online June 30, 2016; DOI: https://doi.org/10.12701/yujm.2016.33.1.13

2,135 View
4 Download

Abstract PDF: BACKGROUND
Prevalence of adenoma in males aged 40-49 years in Korea was higher than expected. The aim of this study was to investigate the prevalence and risk factors of colorectal adenoma in males aged 40-49 years. METHODS: Total 1,902 asymptomatic subjects with a mean age of 47.9±6.7 years, who underwent a screening colonoscopy in a health promotion center of Myongji Hospital from 2010 to 2013 were enrolled in this study. We conducted a case-control study to determine the risk factors for adenoma. The subjects were classified into two groups (adenoma vs. controls). To validate the diagnostic value of carcinoembryonic antigen (CEA) for adenoma, area under the receiver operating characteristic curve (AUROC) was calculated. RESULTS: At least one colorectal adenoma was identified in 385 subjects (20.2%). Among these 385 subjects, 372 subjects were found to have a non-advanced adenoma, 13 subjects had an invasive adenoma. One subject had cancer. Male sex, age, smoking, metabolic syndrome, and elevated CEA level were significantly associated with a colorectal adenoma in univariate analysis. However, metabolic syndrome was not significant in multivariate analysis. In the male group, the AUROC of CEA for colorectal adenoma was 0.600 (0.543 to 0.656) in non-smokers under 50 years of age, and 0.615 (0.540 to 0.690) in smokers under 50 years of age. CONCLUSION: Male sex, smoking, and high levels of CEA seem to be associated with colorectal adenoma. High levels of CEA and smoking may be diagnostic markers for any colorectal adenoma in Korean males aged 40-49 years.

First
Prev
Page of 1
Next
Last

Search